MEM 1003: Phase IIa data

In a double-blind, placebo-controlled Phase IIa trial in 84 patients, MEM 1003 missed all primary and secondary endpoints. MEMY said 26% of patients receiving MEM 1003 showed a 50% improvement from ba...